Thymic emigration patterns in patients with type 2 diabetes treated with metformin

Immunology

Volumn 146, Issue 3, 2015, Pages 456-469

  Dworacki, Grzegorz ^a   Urazayev, Olzhas ^b   Bekmukhambetov, Yerbol ^b   Iskakova, Saule ^b   Frycz, Bartosz A ^a   Jagodziński, Paweł P ^a   Dworacka, Marzena ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WEST KAZAKHSTAN MARAT OSPANOV STATE MEDICAL UNIVERSITY   (Kazakhstan)

Author keywords

Diabetes type 2; Metformin; Recent thymic emigrants; Thymic output

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7 RECEPTOR; METFORMIN; ANTIDIABETIC AGENT; IL2RG PROTEIN, HUMAN; IL7 PROTEIN, HUMAN; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR;

AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; LYMPHOCYTE STRUCTURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD POLYMORPHONUCLEAR CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; T CELL RECEPTOR EXCISION CIRCLE; THYMUS FUNCTION; CASE CONTROL STUDY; CELL MOTION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; THYMUS;

AGED; CASE-CONTROL STUDIES; CELL MOVEMENT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC MEMORY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-7; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MALE; METFORMIN; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; THYMUS GLAND;

EID: 84943599887     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12522     Document Type: Article

References (47)

1. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123-32.
2. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994; 179:1127-35.
3. Jamieson BD, Douek DC, Killian S et al. Generation of functional thymocytes in the human adult. Immunity 1999; 10:569-75.
4. Hazenberg MD, Otto SA, Cohen Stuart JW et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6:1036-42.
5. Dion ML, Sékaly RP, Cheynier R. Estimating thymic function through quantification of T-cell receptor excision circles. Methods Mol Biol 2007; 380:197-213.
6. Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol 2012; 24:209-17.
7. Sasson SC, Zaunders JJ, Zanetti G et al. Increased plasma interleukin-7 level correlates with decreased CD127 and increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 2006; 193:505-14.
8. + T-cells in HIV-1 infection. PLoS One 2012; 7:e31148.
9. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23:3-13.
10. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16:1103-23.
11. Pedicino D, Giglio AF, Galiffa VA, Cialdella P, Trotta F, Graziani F, Liuzzo G. Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions. Int J Cardiol 2013; 166:572-83.
12. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122:253-70.
13. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010; 53:1631-7.
14. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322-6.
15. Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Diab Vasc Dis Res 2014; 11:133-73.
16. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1, 5 -Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29:1214-9.
17. Chusney GD, Philippa M, Pickup JC. Comparison of micro-enzymatic and high performance liquid chromatographic methods for the assay of serum 1, 5-anhydroglucitol. Clin Chim Acta 1995; 235:91-9.
18. Dworacka M, Winiarska H. The application of plasma 1, 5-anhydro-d-glucitol for monitoring type 2 diabetic patients. Dis Markers 2005; 21:127-32.
19. Dungan KM. 1, 5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008; 8:9-19.
20. Weykamp C, John WG, Mosca A et al. The IFCC reference measurement system for HbA1c: A 6-year progress report. Clin Chem 2008; 54:240-8.
21. Berthold F. Isolation of human monocytes by Ficoll density gradient centrifugation. Blut 1981; 43:367-71.
22. Motta M, Chiarini M, Ghidini C, Zanotti C, Lamorgese C, Caimi L, Rossi G, Imberti L. Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patients. J Transl Med 2010; 8:111.
23. Krenger W, Schmidlin H, Cavadini G, Holländer GA. On the relevance of TCR rearrangement circles as molecular markers for thymic output during experimental graft-versus-host disease. J Immunol 2004; 172:7359-67.
24. Sottini A, Ghidini C, Zanotti C et al. Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clin Immunol 2010; 136:217-27.
25. Abbas A. Diseases of immunity. In: Kumar V, Abbas A, Fausto N, eds. Robbins and Cotran, Pathologic Basis of Disease. Philadelphia: W. B. Saunders, 2004:193-267.
26. + human T lymphocytes expressing β7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2006; 34:1429-34.
27. Hale LP, Buckley RH, Puck JM, Patel DD. Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. Clin Immunol 2004; 110:63-70.
28. Sfikakis PP, Gourgoulis GM, Moulopoulos LA, Kouvatseas G, Theofilopoulos AN, Dimopoulos MA. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest 2005; 35:380-7.
29. Gruia AT, Barbu-Tudoran L, Mic AA, Ordodi VL, Paunescu V, Mic FA. Arachidonic acid accumulates in the stromal macrophages during thymus involution in diabetes. Histochem Cell Biol 2011; 136:79-92.
30. + T cells with skewing toward a Treg- and Th2-dominated phenotype. Diabetes 2012; 61:401-8.
31. Yang H, Youm YH, Vandanmagsar B, Rood J, Kumar KG, Butler AA, Dixit VD. Obesity accelerates thymic aging. Blood 2009; 114:3803-12.
32. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 2007; 120:435-46.
33. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol 2010; 22:507-13.
34. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty area challenge for the development of more effective influenza vaccines. Vaccine 2012; 30:2060-7.
35. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674-85.
36. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J 2014; 38:330-6.
37. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 2013; 23:808-15.
38. Inzucchi SE, Bergenstal RM, Buse JB et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-79.
39. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8:e71583.
40. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 2015; 112:1809-14.
41. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460:103-7.
42. Green AS, Chapuis N, Maciel TT et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116:4262-73.
43. Malchow S, Leventhal DS, Nishi S et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 2013; 339:1219-24.
44. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-11.
45. Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012; 24:429-35.
46. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005; 5:844-52.
47. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 2008; 84:949-57.